GSK plc (NYSE:GSK) on Monday entered into an exclusive strategic collaboration with Sino Biopharmaceutical (SBP Group), through its subsidiary Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (CTTQ), to accelerate bepirovirsen in mainland China at launch.

Bepirovirsen is under priority regulatory review in China for chronic hepatitis B (CHB).

GSK Partners With Sino Biopharmaceutical On Hepatitis B Drug

The partnership centers on bepirovirsen, an investigational treatment for chronic hepatitis B currently under priority regulatory review in China. Under the agreement, CTTQ will oversee importation, distribution, hospital access, and promotional activities for the therapy in mainland China.

GSK will continue to serve as the marketing authorization holder and retain responsibility for regulatory matters, quality oversight, pharmacovigilance, and global medical strategy.

GSK licensed bepirovirsen from Ionis Pharmaceuticals Inc. (NASDAQ:IONS) and collaborated with them on its development.

Read ...